Stock TH THERATECHNOLOGIES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Theratechnologies Inc.

Equities

TH

CA88338H7040

Pharmaceuticals

Market Closed - Toronto S.E.
Other stock markets
 03:59:51 2024-04-29 pm EDT 		5-day change 1st Jan Change
1.79 CAD -0.56% Intraday chart for Theratechnologies Inc. -3.24% -16.36%
Apr. 10 Update On Theratechnologies; Down More Than 5% On TSX As Q1 Net Loss Narrows, Awaits FDA Decision MT
Apr. 10 Theratechnologies Up Near 6% In US Premarket As Q1 Net Loss Narrows, Accelerates Phase 1 Trial of Ovarian Cancer Drug MT

Valuation

Fiscal Period: November 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 312.4 231 400.5 278.8 105.8 82.3 - -
Enterprise Value (EV) 1 312.4 231 400.5 278.8 105.8 82.3 82.3 82.3
P/E ratio -19.1 x -7.99 x -9.63 x -4.31 x -1.75 x -11.4 x -7.48 x -6.44 x
Yield - - - - - - - -
Capitalization / Revenue 3.72 x 2.79 x 4.46 x 2.56 x 0.96 x 0.69 x 0.64 x 0.57 x
EV / Revenue 3.72 x 2.79 x 4.46 x 2.56 x 0.96 x 0.69 x 0.64 x 0.57 x
EV / EBITDA 728 x -26 x -21.4 x -8.71 x -26.9 x 4.29 x 3.26 x 2.38 x
EV / FCF -33,525,895 x -13,588,515 x - - - - 3,854,097 x 1,594,765 x
FCF Yield -0% -0% - - - - 0% 0%
Price to Book 9.46 x 57.2 x 17.5 x -9.23 x -3.51 x -2.55 x -2.65 x -4.74 x
Nbr of stocks (in thousands) 19,238 19,253 23,780 23,785 49,202 45,980 - -
Reference price 2 16.24 12.00 16.84 11.72 2.150 1.790 1.790 1.790
Announcement Date 2/25/20 2/25/21 2/24/22 2/28/23 2/21/24 - - -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: November 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 84 82.66 89.73 108.7 110.5 119.9 128.1 145.6
EBITDA 1 0.4292 -8.877 -18.75 -32.01 -3.938 19.17 25.25 34.64
EBIT 1 -11.31 -22.47 -32.43 -54.2 -14.36 8.008 -2.701 -23.79
Operating Margin -13.47% -27.19% -36.14% -49.85% -13% 6.68% -2.11% -16.34%
Earnings before Tax (EBT) 1 -16.61 -28.37 -40.69 -63.56 -31.81 -6.999 -17.25 -26.67
Net income 1 -16.61 -28.37 -40.77 -64.16 -32.38 -6.683 -13.38 -22
Net margin -19.77% -34.32% -45.44% -59% -29.3% -5.58% -10.45% -15.11%
EPS 2 -0.8504 -1.502 -1.748 -2.721 -1.229 -0.1575 -0.2392 -0.2778
Free Cash Flow -9.319 -17 - - - - 21.36 51.61
FCF margin -11.09% -20.57% - - - - 16.67% 35.45%
FCF Conversion (EBITDA) - - - - - - 84.57% 148.97%
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 2/25/20 2/25/21 2/24/22 2/28/23 2/21/24 - - -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: November 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 24.1 23.4 24.97 28.7 29.09 26.82 23.28 28.09 31.69 22.08 29.81 31.06 35.33
EBITDA 1 -7.07 - -15.17 - - -5.244 -8.086 2.91 6.7 -0.3357 2.672 5.723 9.549
EBIT 1 -10.36 -9.735 -27.16 -7.612 -7.753 -7.285 -10.54 0.073 3.608 -3.053 2.396 3.628 5.134
Operating Margin -43% -41.6% -108.79% -26.52% -26.65% -27.16% -45.27% 0.26% 11.38% -13.82% 8.04% 11.68% 14.53%
Earnings before Tax (EBT) 1 -12.7 -11.36 -29.29 -10.2 -10.58 -13.94 -13.11 -0.8377 -3.624 -5.941 -2.118 -0.2337 1.133
Net income 1 -12.72 -11.39 -29.45 -10.41 -10.77 -14.07 -13.28 -1.008 -3.723 -6.09 -2.164 -0.5077 0.5852
Net margin -52.79% -48.67% -117.95% -36.27% -37.02% -52.46% -57.06% -3.59% -11.75% -27.58% -7.26% -1.63% 1.66%
EPS 2 -0.5141 -0.4539 -1.261 -0.4414 -0.4898 -0.5918 -0.5268 -0.0405 -0.0405 -0.1359 -0.0457 -0.0183 -
Dividend per Share - - - - - - - - - - - - -
Announcement Date 2/24/22 4/13/22 7/14/22 10/13/22 2/28/23 4/12/23 7/12/23 9/26/23 2/21/24 4/10/24 - - -
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: November 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow -9.32 -17 - - - - 21.4 51.6
ROE (net income / shareholders' equity) -50.3% -162% - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 1.720 0.2100 0.9600 -1.270 -0.6100 -0.7000 -0.6800 -0.3800
Cash Flow per Share 2 -0.2300 -0.8800 -0.8000 -0.8400 -0.2900 0.1900 0.3900 0.7700
Capex 1 1.61 0.04 - 1.34 0.43 0.68 0.34 0.34
Capex / Sales 1.92% 0.05% - 1.23% 0.39% 0.57% 0.27% 0.23%
Announcement Date 2/25/20 2/25/21 2/24/22 2/28/23 2/21/24 - - -
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Theratechnologies Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.79 CAD
Average target price
8 CAD
Spread / Average Target
+346.93%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
THERATECHNOLOGIES INC. Stock Theratechnologies Inc.
-16.36% 60.29M
CSL LIMITED Stock CSL Limited
-3.45% 87.17B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.97% 40.1B
UCB Stock UCB
+57.54% 25.12B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-14.82% 15.59B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-8.82% 12B
INCYTE CORPORATION Stock Incyte Corporation
-16.29% 11.8B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-41.58% 11.8B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+7.27% 8.81B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-10.53% 8.24B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. TH Stock
  4. Financials Theratechnologies Inc.